Main characteristics of the patients at diagnosis of DLBCL and at the time of starting treatment with T/L
| . | Global ITT series (n = 99) . | Efficacy cohort (n = 83) . |
|---|---|---|
| At diagnosis | ||
| Age >60 years | 86 (87) | 72 (87) |
| Sex (M/F) | 48 (48)/51 (51) | 39 (47)/44 (53) |
| ECOG PS of >1 | 24 (24) | 16 (19) |
| Ethnicity | ||
| White | 96 (97) | 80 (96) |
| Hispanic | 2 (2) | 2 (2) |
| Other | 1 (1) | 1 (1) |
| Ann Arbor stage III-IV | 82 (83) | 67 (81) |
| B-symptoms | 42 (42) | 35 (42) |
| R-IPI of 3-5 | 70 (71) | 55 (66) |
| Response to first line | ||
| CR | 37 (37) | 40 (48) |
| Less than CR | 62 (63) | 43 (52) |
| At T/L | ||
| Median age (range), y | 78 (47-93) | 78 (47-93) |
| Age group, y | ||
| 18-60 | 11 (11) | 9 (11) |
| 61-79 | 47 (47) | 40 (48) |
| ≥80 | 41 (41) | 34 (41) |
| ECOG PS of >1 | 38 (38) | 27 (32) |
| Ann Arbor stage III-IV | 68 (69) | 56 (67) |
| B-symptoms | 34 (34) | 26 (31) |
| R-IPI 3-5 | 59 (60) | 44 (53) |
| Median CIRS (range) | 6 (0-21) | 6 (0-21) |
| Median previous lines (range) | 2 (1-13) | 2 (1-13) |
| Previous lines | ||
| 1 | 44 (44) | 40 (48) |
| 2 | 27 (27) | 21 (25) |
| >2 | 28 (28) | 22 (26) |
| Previous CAR-T therapy | ||
| Yes | 6 (6) | 5 (6) |
| No | 93 (94) | 78 (94) |
| Disease status | ||
| Relapsed | 40 (40) | 37 (45) |
| Progressive/refractory | 59 (60) | 46 (55) |
| L-MIND noneligibility | 76 (77) | 61 (73) |
| Causes for L-MIND noneligibility | ||
| >3 previous lines | 14 (14) | 11 (13) |
| ECOG PS of 3-4 | 10 (10) | 4 (5) |
| Double-hit HGL | 6 (6) | 5 (6) |
| Cytopenia | 9 (9) | 6 (7) |
| Renal failure | 12 (12) | 10 (12) |
| Primary refractory | 62 (63) | 48 (58) |
| . | Global ITT series (n = 99) . | Efficacy cohort (n = 83) . |
|---|---|---|
| At diagnosis | ||
| Age >60 years | 86 (87) | 72 (87) |
| Sex (M/F) | 48 (48)/51 (51) | 39 (47)/44 (53) |
| ECOG PS of >1 | 24 (24) | 16 (19) |
| Ethnicity | ||
| White | 96 (97) | 80 (96) |
| Hispanic | 2 (2) | 2 (2) |
| Other | 1 (1) | 1 (1) |
| Ann Arbor stage III-IV | 82 (83) | 67 (81) |
| B-symptoms | 42 (42) | 35 (42) |
| R-IPI of 3-5 | 70 (71) | 55 (66) |
| Response to first line | ||
| CR | 37 (37) | 40 (48) |
| Less than CR | 62 (63) | 43 (52) |
| At T/L | ||
| Median age (range), y | 78 (47-93) | 78 (47-93) |
| Age group, y | ||
| 18-60 | 11 (11) | 9 (11) |
| 61-79 | 47 (47) | 40 (48) |
| ≥80 | 41 (41) | 34 (41) |
| ECOG PS of >1 | 38 (38) | 27 (32) |
| Ann Arbor stage III-IV | 68 (69) | 56 (67) |
| B-symptoms | 34 (34) | 26 (31) |
| R-IPI 3-5 | 59 (60) | 44 (53) |
| Median CIRS (range) | 6 (0-21) | 6 (0-21) |
| Median previous lines (range) | 2 (1-13) | 2 (1-13) |
| Previous lines | ||
| 1 | 44 (44) | 40 (48) |
| 2 | 27 (27) | 21 (25) |
| >2 | 28 (28) | 22 (26) |
| Previous CAR-T therapy | ||
| Yes | 6 (6) | 5 (6) |
| No | 93 (94) | 78 (94) |
| Disease status | ||
| Relapsed | 40 (40) | 37 (45) |
| Progressive/refractory | 59 (60) | 46 (55) |
| L-MIND noneligibility | 76 (77) | 61 (73) |
| Causes for L-MIND noneligibility | ||
| >3 previous lines | 14 (14) | 11 (13) |
| ECOG PS of 3-4 | 10 (10) | 4 (5) |
| Double-hit HGL | 6 (6) | 5 (6) |
| Cytopenia | 9 (9) | 6 (7) |
| Renal failure | 12 (12) | 10 (12) |
| Primary refractory | 62 (63) | 48 (58) |
Data are presented as n (%) unless otherwise specified.
M/F, male/female.